Professor Thomas Bein is affiliated with the Department of Chemistry at Ludwig-Maximilians-Universität München (LMU) , where he leads the Functional Nanosystems research group. His work focuses on synthesizing and characterizing nanostructured materials with applications in energy, catalysis, and biomedical delivery. Mesoporous nanoparticles for drug delivery Semiconductor nano-morphologies for photovoltaics Photoelectrochemical water splitting Metal-organic frameworks (MOFs) Electroactive networks His research emphasizes atomic-scale control of material architectures using self-assembly, hydrogen bonding, and covalent interactions, enabling precise tuning of electronic, optical, and catalytic properties. A review of his recent publications reveals cutting-edge investigations into covalent organic frameworks (COFs), perovskite-inspired solar materials, and functional nanoparticle systems. Key trends include optimizing energy conversion efficiency, enhancing stability in optoelectronic devices, and exploring bio-compatible nanocarriers for targeted therapies. Professor Bein’s group actively contributes to interdisciplinary projects at the intersection of chemistry, physics, and biomedical engineering, with ongoing collaborations in solar energy, sustainable materials, and nanomedicine.
Thomas Walz, PhD, is a Professor at The Rockefeller University and Head of the Laboratory of Molecular Electron Microscopy. Previously, he held positions as Assistant, Associate, and Professor at Harvard Medical School (1999–2015) and was an Investigator at the Howard Hughes Medical Institute (2008–2015). He earned his PhD and BS in biophysics from the University of Basel, Switzerland, and completed postdoctoral research at the University of Sheffield. Walz completed his education at the Biozentrum, University of Basel, Switzerland, where he received his Diploma in Biophysics (1992) and PhD in Biophysics (1996). He furthered his training as a postdoctoral researcher at the University of Sheffield (1996–1999). His research focuses on understanding membrane-related processes and the structural biology of membrane proteins in lipid environments. Utilizing cryo-electron microscopy and nanodisc technology, he investigates how lipid bilayers influence membrane protein structure and function. Key areas include mechanosensitive channels, T-cell receptor dynamics, and telomere maintenance mechanisms. Collaborations with the de Lange lab explore the CST-Polα/primase complex's role in telomere regulation. Walz has been recognized with the Genzyme Award for Outstanding Achievement in Biomedical Sciences (2004) and continues to contribute to advancements in structural biology and membrane protein research. While specific student advisees are not listed, Walz actively mentors through his roles in the David Rockefeller Graduate Program and Tri-Institutional programs. His research is supported by grants and institutional funding, though specific grants are not detailed here. He directs the Laboratory of Molecular Electron Microscopy at Rockefeller, a hub for innovative structural biology and membrane protein studies. The lab collaborates widely, integrating cryo-EM with electrophysiology and molecular dynamics simulations.
Sriram Subramaniam is a Professor in the Department of Biochemistry and Molecular Biology at the University of British Columbia (UBC) and holds the Gobind Khorana Canada Excellence Research Chair in Precision Cancer Drug Design. His research leverages cryo-electron microscopy (cryo-EM) to advance structural biology and drug design, focusing on protein dynamics and therapeutic target identification. Education: PhD in Physical Chemistry (1987) from Stanford University; MSc in Chemistry (1981) from Indian Institute of Technology, Kanpur. Subramaniam's interdisciplinary work combines cryo-EM with computational tools and molecular biology to study protein structures at atomic resolution. His lab has pioneered cryo-EM applications in precision medicine, including mapping small molecule drugs on patient-specific cancer mutants. Recent publications (2024-2022) highlight his contributions to understanding SARS-CoV-2 immune evasion, structural mechanisms of ATPases, and AI integration in structural biology. His research spans viral entry mechanisms, CRISPR systems, and neurodegenerative disease pathways. Scientific Awards: Gobind Khorana Canada Excellence Research Chair NIH Director’s Award for Scientific Excellence Fellow of the Biophysical Society Breakthrough Prize nomination Based at the Djavad Mowafaghian Center for Brain Health, Subramaniam leads the Program in Cryo-EM Guided Drug Design, contributing to over 177 peer-reviewed publications with a career h-index of 58 and citations exceeding 12,340.
Professor Todd Squires is a distinguished faculty member in the Department of Chemical Engineering at the University of California, Santa Barbara, within the Robert Mehrabian College of Engineering. His research focuses on the fundamental principles of transport phenomena as applied to interfaces, membranes, and complex fluids, employing theoretical, computational, and experimental approaches to address significant challenges in micro-scale fluid mechanics. Dr. Squires' educational background includes: BS in Physics, UCLA (1995) BA in Russian Language and Literature, UCLA (1995) PhD in Physics, Harvard University (2002) His research interests span microfluidics and electrokinetics, active and nonlinear microrheology of complex materials, polymer dynamics and sensors, with particular emphasis on non-linear electrokinetic flows, interfacial rheology, and the self-assembly of nanostructured materials. His work bridges fundamental fluid mechanics with practical applications in microfluidic devices, energy storage, and biomedical systems, demonstrating the versatility of this fascinating field. Analysis of Professor Squires' recent publications reveals a consistent focus on interfacial phenomena, with particular attention to the rheological properties of fluid interfaces, particle dynamics in complex fluids, and novel microfluidic techniques for measuring and manipulating these systems. His research demonstrates strong interdisciplinary connections between chemical engineering, physics, and materials science, with applications spanning energy storage, biomedical engineering, and environmental systems. Professor Squires has received numerous prestigious awards and honors: 2018 Robert W. Vaughan Lecture in Chemical Engineering, Caltech 2015 Elected Fellow of the American Physical Society 2013 Mid-Career Award, American Electrophoresis Society 2012 The Dudley Saville Memorial Lecture at Princeton 2010 Pierre Gilles de Gennes Prize 2010 Allan P. Colburn Memorial Lectureship, University of Delaware 2009 Francois Frenkiel Award for Fluid Mechanics 2009 Camille Dreyfus Teacher-Scholar Award 2008 Beckman Young Investigator 2007 NSF CAREER Award 2005 'Rising Star' - Chronicle of Higher Education As principal investigator of the Squires Group, Professor Squires leads a dynamic research team that combines experimental, theoretical, and computational approaches to investigate transport phenomena at interfaces. His work has been supported by major funding agencies including the National Science Foundation, with his CAREER award indicating early recognition of his potential as both researcher and educator. While specific grant details aren't provided in the source material, his extensive publication record and prestigious awards suggest robust and sustained research funding. The Squires Group maintains state-of-the-art laboratory facilities for studying micro-scale fluid mechanics, including specialized equipment for microrheology measurements, microfluidic device fabrication, and interfacial characterization. Their research environment fosters collaboration across disciplines, with connections to materials science, physics, and biomedical engineering researchers at UCSB and beyond.
Alexis Battle is an Associate Professor at Johns Hopkins University with appointments in Biomedical Engineering , Computer Science , and Genetic Medicine (secondary). She directs the Malone Center for Engineering in Healthcare and serves as Deputy Director of the Data Science and AI Institute . Educated at Stanford University (PhD in Computer Science, 2013), Battle transitioned to academia after leadership roles at Google. Research Focus: Battle’s work bridges genomics and machine learning , emphasizing the impact of genetic variation on human health. Her lab develops tools like Watershed to predict functional effects of rare variants, aiming to enhance rare disease diagnosis. Key themes include non-coding DNA analysis , personalized genomics , and systems biology , with applications in cardiovascular disease and neurodegenerative disorders . Publications & Awards: Over 60 peer-reviewed articles in journals like Nature , Science , and Genome Biology , with recent emphasis on single-cell transcriptomics , multiomics integration , and telomere biology . Recipient of the President’s Frontier Award (2022), Microsoft Investigator Fellowship (2019), and Searle Scholar (2016). Scientific Awards: 2022 President’s Frontier Award 2019 Microsoft Investigator Fellowship 2019 Johns Hopkins Discovery Award 2017 Johns Hopkins Catalyst Award 2016 Searle Scholar Advising & Funding: Mentors 11 PhD students, 3 undergraduates, and postdoctoral fellows. Her research is funded by NIH, Searle Scholars, and institutional grants. The Battle Lab collaborates on projects like the GTEx Consortium , focusing on gene regulation and clinical genomics .
Dr. Pascal Syren is a **Researcher** and **Resident** at Heidelberg University Hospital (UKHD), affiliated with the **Department of Cardiology, Angiology, and Pulmonology** and the **Heidelberg Center for Cardiac Arrhythmias**. His academic role includes contributing to the **Group of Molecular and Translational Cardiac Electrophysiology**, focusing on epigenetic and molecular mechanisms underlying cardiac arrhythmias and heart failure. He holds a PhD from Heidelberg University (2021) on histone deacetylases' influence in cardiac electrophysiology. **Research Interests**: Cardiac electrophysiology, epigenetic regulation (HDACs), ventricular and atrial arrhythmias, echocardiography, and translational cardiology. His work spans basic science to clinical applications, emphasizing ion channel remodeling and therapeutic targets for heart rhythm disorders. **Awards**: Recipient of the **Ernst & Berta Grimmke Foundation Research Grant (2023–2024)** and **Otto-Hess Scholarship (2017–2018)** from the German Cardiac Society. His research bridges molecular mechanisms with clinical cardiology, with contributions to understanding HDAC2's role in action potential dynamics. **Publications**: Over 8 peer-reviewed articles (2016–2025) in journals like *Basic Research in Cardiology* and *Cells*, focusing on histone deacetylase pathways, atrial fibrillation, and ventricular arrhythmia models. Recent work explores neonatal cardiomyocyte electrophysiology and TREK-1 potassium channels in heart failure. **Affiliations**: Active member of the **German Cardiac Society (DGK)** and **European Society of Cardiology (ESC)**, contributing to interdisciplinary cardiac arrhythmia research at Heidelberg's medical faculty.
Hai-Quan Mao is a Professor of Materials Science and Engineering at Johns Hopkins University, with a joint appointment in the Biomedical Engineering Department (School of Medicine). He directs the Institute for NanoBioTechnology (INBT) and leads the Translational Tissue Engineering Center. His research focuses on biomaterials, regenerative engineering, and immunoengineering, particularly developing nanomaterials for therapeutic delivery and tissue regeneration. Mao holds 35 U.S. patents, co-founded two biotech companies, and received prestigious awards including National Academy of Inventors Fellow and NSF CAREER Award. Education: BS in Chemistry (1988) and PhD in Polymer Chemistry (1993) from Wuhan University. Postdoctoral training at Johns Hopkins (1995–1998), followed by roles at Johns Hopkins Singapore (1999–2003) before joining the Whiting School faculty. Research emphasizes nanofiber scaffolds for liver/nerve regeneration, DNA/lipid nanoparticle engineering for gene therapy, and artificial lymph node matrices for immunotherapy. His lab translates biomaterials innovations into clinical applications, with NIH-funded projects addressing cancer, malaria, and tissue damage. Awards include over 60 provisional patents, multiple Johns Hopkins translational awards, and Thalheimer Awards for research. He serves as associate editor of Biomaterials and editorial board member of major journals. Lab activities include scalable nanoparticle manufacturing, machine learning for material design, and collaborations with industry/clinical partners. Recent work includes lipid nanoparticle optimization for mRNA vaccines and exosome-based therapies for Crohn’s disease.
Kristian Helin is Chief Executive and President of The Institute of Cancer Research (ICR), London, and a Professor with affiliations at the University of Copenhagen and Memorial Sloan Kettering Cancer Center. He founded/directed the Biotech Research & Innovation Centre (BRIC), Centre for Epigenetics, and Danish Stem Cell Center. His research focuses on epigenetic regulation, cancer biology, and stem cell differentiation. Education: Ph.D. Molecular Biology, University of Copenhagen (1991) M.Sc. Chemical Engineering, Technical University of Denmark (1988) Research Interests: Helin's work deciphers molecular mechanisms in cancer, emphasizing epigenetic drivers (e.g., H3K4/H3K36 methylation), transcriptional control, and therapeutic targeting. His lab identified E2F transcription factors, linked epigenetic dysregulation to leukemia/lymphoma, and develops drugs targeting kinases/epigenetic enzymes. Research spans acute myeloid leukemia, B-cell lymphoma, and solid tumors using CRISPR screens and preclinical models. Publication Trends: Recent articles (2023-2025) focus on epigenetic therapy, chromatin remodeling, and kinase signaling in cancer. Key themes include targeting NSD1/KDM5C/RIOK2 enzymes, combination therapies (EZH2/DOT1L inhibitors), and metabolic regulation in leukemia. Studies bridge basic mechanisms (enhancer regulation, insulator accessibility) with translational applications. Awards: Anders Jahre Prize (2014), ERC Advanced Grant (2011), Novo Nordisk Prize (2008) Memberships: Academia Europaea, Royal Danish Academy, EMBO Leadership: Helin co-founded EpiTherapeutics (acquired by Gilead) and leads the Epigenetics and Cancer lab at ICR. His team investigates AML pathogenesis and chromatin complexes like HUSH/NURF. Grants include ERC funding and innovation prizes.
Thomas Michaels is an Assistant Professor at the Department of Biology, ETH Zürich, leading the Michaels Group . His research focuses on theoretical models of biomolecular condensates and protein aggregation in biological systems. Research Themes : Protein aggregation, liquid-liquid phase separation, membrane biophysics, and the role of condensates in neurodegenerative diseases like Alzheimer’s and Parkinson’s. Collaborative Approach : Integrates theoretical physics, control theory, and computational biology with experimental validation to design therapeutic strategies. Recent Publications highlight his work on amyloid formation mechanisms, lipid interactions, and phase-separated compartments as biochemical reactors. His group trains PhD students in systems biology and biocondensate physics.
Marcus Smith is an Associate Professor in Law at the Charles Sturt University , where he teaches LAW222 Technology Law and directs the Bachelor of Laws program. He holds advanced degrees from the Australian National University (PhD, LLM) and the University of Cambridge (MPhil). His research spans technology law and regulation , focusing on genomic data governance biometric identification AI ethics blockchain policy cybersecurity surveillance law He leads the Contemporary Threats to Australian Security research group and serves as Chief Investigator on an NHMRC-funded project (MRF2015531) addressing genomic dataset governance. His recent work analyzes algorithmic bias in facial recognition AI in healthcare blockchain's regulatory challenges post-pandemic cybercrime surveillance ethics data security frameworks He actively supervises PhD and honours students in technology law and contributes to law reform through submissions to international bodies like the UN Human Rights Council .
Katja Hose is a Full Professor of Data Management at TU Wien's DBAI research unit, heading the Data Management and Knowledge-Driven AI Lab. She previously held a Poul Due Jensen Foundation Professorship at Aalborg University. Her research focuses on data and knowledge engineering, including graph databases, knowledge graphs, querying, analytics, and machine learning, with interdisciplinary applications in bioscience, healthcare, and environmental assessment. Education: PhD in Computer Science (Ilmenau University of Technology, 2009), Postdoc at Max Planck Institute for Informatics (2009–2012). Academic roles include Program Co-Chair for ISWC 2024 and EDBT 2023, and editorial board membership at VLDBJ and TGDK. She leads projects like TARGET (health virtual twins) and ARMADA (data management). Research Interests: Knowledge Graphs, Semantic Web, Big Data, Machine Learning, Data Integration, and Provenance Systems. Key contributions include SHACL shape extraction, conversational data analytics, and environmental knowledge graphs. Awards include the 2025 Distinguished Meta-Reviewer Award and 2024 Manfred Paul Award. Advising and Grants: Supervised students including E. Pürmayr (Diploma Thesis 2025). Active in EU projects (TARGET, ARMADA) and grant coordination. Labs/Teams: DMKI Lab at TU Wien, collaborating with interdisciplinary teams in healthcare and environmental science.
Britt Adamson is an Associate Professor in the Department of Molecular Biology and the Lewis-Sigler Institute for Integrative Genomics at Princeton University, where she serves as Director of the Undergraduate Program in Quantitative and Computational Biology. Her lab investigates molecular networks in human cells with focus on stress response mechanisms and genome editing technologies. She received her B.S. in Biology from the Massachusetts Institute of Technology (2005) and Ph.D. in Genetics and Genomics from Harvard University (2012), followed by postdoctoral training at UCSF under Jonathan Weissman supported by a Damon Runyon Cancer Research Foundation Fellowship. Adamson's research centers on how cells organize stress response networks during DNA damage and endoplasmic reticulum stress, developing CRISPR-based functional genomics and single-cell sequencing tools to map molecular behaviors. Her work bridges fundamental cell biology with therapeutic applications in genome editing. Analysis of her 15 most recent publications reveals dominant themes in precision genome editing (prime/base editing optimization) and systematic dissection of DNA repair pathways through combinatorial CRISPR screening. Her lab consistently integrates computational approaches with high-resolution experimental techniques to uncover context-dependent cellular behaviors. Her scientific recognitions include: Damon Runyon Cancer Research Foundation Postdoctoral Fellowship Princeton IP Accelerator Award (2025) STAT Who to Know: 10 Scientists leading a new generation of gene editors (2024) Adamson actively mentors eight graduate students (including alumni Ann Cirincione and Jun Hussmann) and two postdocs, with research funded through institutional awards and collaborative grants. Her lab's technological developments have enabled projects spanning virology, immunology, and developmental biology. The Adamson Lab operates within Princeton's Lewis-Sigler Institute for Integrative Genomics, fostering an interdisciplinary environment that merges cell biology, genomics, and computational science. Current projects focus on improving prime editing efficiency and understanding stress response adaptation in disease contexts.
Wing Lam is an Associate Research Scientist in the Department of Pharmacology at the Yale School of Medicine. He holds a BSc in Molecular Biology and a PhD in Biochemical Pharmacology from City University of Hong Kong, followed by postdoctoral training at Yale. His research focuses on developing traditional Chinese medicine (TCM) formulations as adjuvants for cancer therapy, notably YIV-906, which enhances chemotherapy efficacy and mitigates intestinal toxicity. Lam also pioneered the STAR database for herbal drug discovery and the Mechanism-Based Quality Control (MBQC) platform for botanical drug standardization. Education: BSc (Hons) Molecular Biology, City University of Hong Kong, 1995 PhD Biochemical Pharmacology, City University of Hong Kong, 1999 Postdoc, Pharmacology, Yale University, 1999-2002 His research interests span cancer pharmacology, TCM modernization, and mitochondrial toxicity mechanisms. Key projects include YIV-906’s role in enhancing anti-PD1 and CAR T-cell therapies, developing L-nucleoside analogs like troxacitabine, and investigating tylophorine analogs’ antitumor effects. Lam has co-chaired sessions at multiple Consortium for Globalization of Chinese Medicine (CGCM) meetings and contributed to patents on herbal drug formulations and quality control methods. Recent work explores YIV-906’s potential for inflammatory bowel disease (IBD) and phase II clinical trials for colon and liver cancers. Lam’s publications highlight synergistic drug interactions, mitochondrial DNA depletion mechanisms, and TCM’s evidence-based application in chronic diseases. His grants include studies on PHY906 as an adjuvant in rectal cancer therapy and collaborations with Yiviva, Inc. He maintains active roles in editorial boards, including a special issue on herbal drug quality control in Frontiers in Pharmacology . Lam’s lab is embedded within Dr. Yung-Chi Cheng’s group, focusing on translational pharmacology and botanical drug innovation.
Dr. Steven G. Clarke is a Distinguished Professor at UCLA Department of Chemistry & Biochemistry and director of research at the Molecular Biology Institute . His work bridges protein chemistry , methylation biology , and aging research through studies of spontaneous protein damage and its repair mechanisms. Education: BA in Chemistry and Zoology, Pomona College (magna cum laude, Phi Beta Kappa) PhD in Biochemistry and Molecular Biology, Harvard University (NSF Fellow) Postdoctoral Fellowship at UC Berkeley (Miller Fellow) Dr. Clarke's research focuses on protein isoaspartyl repair via PCMT1/PIMT enzymes , ribosomal protein methylation in Saccharomyces cerevisiae , and PRMT family characterization including PRMT7 and PRMT9. His lab combines biochemical assays , genetic models , and structural analysis to investigate aging mechanisms and disease implications. Recent publications highlight: COQ5 structure-function analysis in coenzyme Q biosynthesis PCMTD1 ubiquitin ligase interactions PRMT7 substrate specificity in histone H2B Protein isoaspartyl impacts on T cell function in lupus Novel PRMT inhibitors for cancer therapy Methionine addiction in osteosarcoma malignancy Major scientific awards: American Chemical Society Ralph F. Hirschmann Award in Peptide Chemistry NIH MERIT Award Ellison Medical Foundation Senior Scholar Award William C. Rose Award, ASBMB UCLA Distinguished Teaching Award (Eby Award winner) Current lab members include PhD candidates Eric Pang (UCSB) and Sining "Cindy" Wang (UCLA), while undergraduates Celeste Medina-Seymoure , Elizabeth Oroudjeva , Olivia Pacheco , and Jasmine Winter contribute to ongoing proteostasis studies. Collaborations with Profs. Jose Rodriguez and Catherine Clarke demonstrate interdisciplinary research approaches.
Michele Klingbeil is a Professor in the Department of Microbiology at the University of Massachusetts Amherst, where she leads the Klingbeil DNA Replication Laboratory. She received her PhD in Cell and Molecular Biology from the University of Toledo in 1996 and previously worked at Johns Hopkins School of Medicine before moving to UMass in July 2007. Her educational background includes: PhD in Cell and Molecular Biology, University of Toledo, 1996 Dr. Klingbeil's research focuses on the unique biology of trypanosomatid parasites, particularly Trypanosoma brucei , the causative agent of African sleeping sickness. Her laboratory investigates two main areas: (1) replication of the unusual mitochondrial DNA network called kinetoplast DNA (kDNA), and (2) nuclear DNA replication initiation. Her work on kDNA is particularly significant as this structure is essential for parasite survival but has no counterpart in mammalian hosts, making it an attractive drug target. She employs a combination of reverse genetics (RNAi), cell biology, and biochemistry to understand the replication and repair mechanisms of kDNA, with a special focus on a family of four DNA polymerases related to bacterial Pol I. Dr. Klingbeil's recent publications reveal her laboratory's deep investigation into mitochondrial DNA polymerases in trypanosomatids, with discoveries showing multiple polymerases having specialized functions in kDNA replication and repair. Her research has established that several of these polymerases are essential for parasite viability, opening new avenues for drug development. She has also made significant contributions to understanding the simplified Origin Recognition Complex in trypanosomatids compared to other eukaryotes. Dr. Klingbeil has received the Thomas G. Lessie Distinguished Lectureship Award for her impact on teaching at the graduate level. Her research is funded by the National Institutes of Health, U.S. Department of Agriculture, the Joeph P. Healey Endowment, and the University of Massachusetts Amherst. She has mentored numerous graduate and undergraduate students, including current PhD candidates Dave Bruhn, Jeniffer Concepción, and Juemin Luo, as well as visiting scholar Eva Vidal Rico. Her former students have gone on to positions at institutions including Dana Farber/Broad Institute, Regis College, and Flagship Ventures. The laboratory regularly participates in scientific conferences including the Molecular Parasitology Meeting at Woods Hole and the Kinetoplastid Molecular Cell Biology conference. Dr. Klingbeil teaches several courses including Parasitology (MICRO 590S), Parasitology Lab (MICRO 590L), Molecular Mechanisms of Pathogenesis (MICRO 797P), Advanced Cell Biology (MCB 641), and Writing in Microbiology (MICRO 360). Her laboratory organizes regular social events including pumpkin carving parties and outings to Six Flags New England and Mt. Sugarloaf.
